Osteomodulin contributes to keloid development by regulating p38 MAPK signaling.

Area of Science:

• Dermatology
• Fibrotic Skin Diseases
• Extracellular Matrix Biology

Background:

• Keloids are fibrotic skin conditions marked by excessive extracellular matrix (ECM) deposition.
• Osteomodulin (OMD) is implicated in modulating ECM deposition.

Purpose of the Study:

• To investigate the role of Osteomodulin (OMD) in keloid fibroblast (KF) ECM synthesis and tumor-like phenotypes.
• To explore the underlying signaling pathways involved in OMD's effects on KFs.

Main Methods:

• Analysis of OMD expression in human keloid and normal skin tissues using qRT-PCR, western blotting, and immunohistochemistry.
• In vitro studies on primary KFs involving OMD silencing/overexpression, TGF-β1 treatment, and p38 MAPK inhibition (SB203580).
• Assessment of KF proliferation, migration, and ECM component (collagen, fibronectin) synthesis.

Main Results:

• OMD expression was significantly higher in keloid tissues and KFs compared to normal skin and fibroblasts.
• OMD silencing inhibited KF proliferation, migration, and ECM synthesis, while OMD overexpression enhanced these processes.
• OMD expression positively correlated with p38 MAPK activation in keloids, and p38 MAPK inhibition reversed OMD's effects on KFs.

Conclusions:

• Elevated OMD expression contributes to keloid pathogenesis by promoting KF hyperproliferation, migration, and excessive ECM production.
• The p38 MAPK signaling pathway is a key mediator of OMD's effects in keloid fibroblasts.
• OMD represents a potential therapeutic target for managing keloid disease.